Hepatic dosing adjustments
The liver is the primary site of drug metabolism for ~75% of all drugs. Hepatic impairment reduces CYP enzyme activity, lowers albumin (affecting protein binding), reduces first-pass extraction, and decreases portal blood flow. This guide covers the Child-Pugh classification system, hepatic extraction ratio, and evidence-based dose adjustment strategies. Key reference: the FDA guidance on pharmacokinetics in hepatic impairment (2003/2020 update) ↗ and EMA hepatic impairment guideline ↗.
Child-Pugh classification for drug dosing
The Child-Pugh score (originally Child-Turcotte, revised by Pugh) is the standard system for classifying hepatic impairment severity in pharmacokinetic studies and drug labelling. FDA and EMA guidance requires sponsors to conduct hepatic impairment PK studies and express results using Child-Pugh classes.
| Parameter | 1 point | 2 points | 3 points |
|---|---|---|---|
| Bilirubin (mg/dL) | <2 | 2–3 | >3 |
| Albumin (g/dL) | >3.5 | 2.8–3.5 | <2.8 |
| INR / PT | <1.7 | 1.7–2.3 | >2.3 |
| Ascites | None | Mild | Moderate–severe |
| Encephalopathy | None | Grade I–II | Grade III–IV |
Calculator reference: MDCalc Child-Pugh calculator ↗. Always verify dose adjustment thresholds against the specific DailyMed prescribing information ↗.
Hepatic extraction ratio and drug clearance
Drug clearance by the liver depends on the hepatic extraction ratio (EH) — the fraction of drug removed from blood during one pass through the liver. This has major implications for which aspect of hepatic function most affects drug exposure:
Flow-limited clearance
Clearance is limited by hepatic blood flow, not enzyme capacity. Examples: morphine ↗, lidocaine, propranolol, verapamil, fentanyl, meperidine. In liver disease: ↓ portal blood flow → ↑ systemic bioavailability (reduced first-pass) → increased Cmax and AUC after oral dosing. IV dosing less affected.
Capacity-limited clearance
Clearance depends on intrinsic enzyme activity (CLint) and protein binding. Examples: warfarin, diazepam, phenytoin, theophylline, chlorpromazine. In liver disease: ↓ enzyme capacity → prolonged half-life and AUC increase. Protein binding changes also alter free drug fraction.
The well-stirred (venous equilibration) model of hepatic clearance is described in NCBI PK reference ↗. Related glossary: clearance ↗, first-pass effect ↗.
Pharmacokinetic changes in hepatic impairment
↑ Bioavailability (oral)
Reduced first-pass extraction for high-extraction drugs → higher F. Leads to higher-than-expected Cmax after standard oral doses. Dose reduction for oral formulations is often needed even when IV dose is unchanged.
↑ Volume of distribution
Low albumin (reduced protein binding) → more free drug → expanded apparent Vd for highly bound drugs. Ascites adds to Vd for hydrophilic drugs. Related: Vd glossary ↗.
↓ Clearance
Reduced CYP enzyme activity (particularly CYP3A4, 2C19, 1A2 affected early; CYP2D6 relatively preserved). Phase II reactions (glucuronidation) better preserved in mild-moderate HI — morphine-6-glucuronide accumulation is an exception.
↑ Half-life
t½ = 0.693 × Vd / CL. Since Vd ↑ and CL ↓, t½ increases substantially in severe HI. Example: diazepam t½ extends from ~40 h to >100 h in severe cirrhosis. Related: half-life glossary ↗.
Key drugs requiring hepatic dose adjustment
| Drug | Extraction | Hepatic adjustment | Note |
|---|---|---|---|
| Morphine ↗ | High (E~0.7) | Reduce dose; extend interval in severe HI | Active metabolite M6G accumulates in severe HI + renal failure |
| Diazepam | Low | Reduce dose 50% in Child-Pugh C | t½ dramatically prolonged; accumulation risk; prefer lorazepam (glucuronidation) |
| Warfarin ↗ | Low | Use with extreme caution; already↑INR baseline | Baseline INR elevation from reduced clotting factor synthesis confounds monitoring |
| Simvastatin | High (CYP3A4) | Contraindicated in active liver disease | All statins carry hepatotoxicity risk; active hepatic disease is a contraindication. Avoid rosuvastatin in Child-Pugh C. |
| Ritonavir ↗ | High (CYP3A4) | No dose change in Child-Pugh A/B; contraindicated in C | Strong CYP3A4 inhibitor — hepatic impairment amplifies DDI risk for co-medications |
| Clopidogrel | Prodrug — CYP2C19 | Use caution; reduced active metabolite formation | Reduced bioactivation in severe HI → reduced antiplatelet effect. Also bleeding risk from portal hypertension. |
Full drug-specific hepatic impairment data: consult DailyMed ↗, NCBI drug dosing in hepatic impairment ↗, or the AASLD liver disease guidelines ↗.
Frequently asked questions
Which scoring system should be used for hepatic dose adjustment — Child-Pugh or MELD?
Child-Pugh score is used for drug dose adjustment because FDA and EMA hepatic impairment guidance and most drug labels categorise patients as Child-Pugh A (mild), B (moderate), or C (severe). MELD score is primarily used for organ transplant prioritisation and mortality prediction — not for pharmacokinetic classification. When in doubt, use Child-Pugh for dosing decisions, and verify against the specific drug label on DailyMed.
What is the intrinsic clearance concept and why does it matter in hepatic impairment?
Intrinsic clearance (CLint) is the liver's inherent metabolic capacity for a drug, independent of blood flow. In hepatic impairment, CLint is reduced due to loss of hepatocytes. For high-extraction drugs (where clearance is limited by blood flow, not enzyme capacity), hepatic disease reduces clearance primarily by decreasing portal blood flow. For low-extraction drugs, reduced enzyme capacity (CLint) directly reduces clearance. The well-stirred model of hepatic extraction accounts for both these mechanisms and is described in standard PK references.
Do prodrugs work differently in hepatic impairment?
Yes — prodrugs requiring hepatic activation (bioactivation) may be less effective in severe hepatic impairment because the activating enzymes are reduced. Examples: clopidogrel (requires CYP2C19/3A4 for active metabolite formation), codeine (requires CYP2D6), enalapril (requires esterases for enalaprilat conversion). In contrast, prodrugs with extra-hepatic activation (e.g. oseltamivir, activated by intestinal/pulmonary esterases) may be relatively preserved.
Which drug classes most commonly require hepatic dose adjustment?
Drug classes most dependent on hepatic metabolism and thus requiring adjustment in significant liver disease: (1) Statins — major CYP3A4/2C9 substrates, hepatotoxicity risk in active liver disease; (2) Benzodiazepines — prolonged sedation due to reduced oxidative metabolism; (3) Opioids — morphine, fentanyl accumulation in severe HI; (4) Antiretrovirals — many are CYP3A4 substrates; (5) Anticoagulants (warfarin) — additionally affected by reduced clotting factor synthesis. Always check DailyMed or the specific FDA labelling.
Can serum albumin or PT/INR be used to predict drug PK changes in liver disease?
Indirectly, yes. Serum albumin reflects hepatic synthetic function and is a component of Child-Pugh score. Low albumin → reduced protein binding for highly bound drugs → higher free fraction → altered Vd and clearance. PT/INR reflects clotting factor synthesis and is another Child-Pugh component. Neither directly measures metabolic enzyme capacity, but Child-Pugh score (which includes both) correlates reasonably well with PK changes in studies of hepatic impairment populations.